RE:RE:RE:RE:RE:RE:AND DOWN WE GO AGAINwell maybe if you decide to be objective, you will have an idea of what I am saying. You are emotionally attached to the stock.
Aristotle for cancer alone in the pre-launch state with no revs should have this trading above $2. Now you add covid testing to it and it is still trading below $1? That is most definitely an eyesore.
I mentioned how the CO lacks capacity right?
Lets look at an example from 1 or 2 weeks ago. Ichor got a contract for testing Canadians returning from the US. That is a good contract. Stagezero is a part of this deal right? - https://www.newswire.ca/news-releases/ichor-blood-services-and-stagezero-life-sciences-launch-virtual-covid-19-pcr-testing-program-for-canadians-returning-home-from-the-us-826974500.html
But did the CEO PR this? Nope. Cos he is as dumb as it gets.
Tripp lacks the basics. Put Aristotle in the hands of a capable CEO and this stock will be flying aleady. This is what you need to understand.